215 related articles for article (PubMed ID: 1355402)
21. Somatostatin receptor-positive primary breast tumors: genetic, patient and tumor characteristics.
Bootsma AH; van Eijck C; Schouten KK; Reubi JC; Waser B; Foekens JA; van Pel R; Zwarthoff EC; Lamberts SW; de Klein A
Int J Cancer; 1993 May; 54(3):357-62. PubMed ID: 8099570
[TBL] [Abstract][Full Text] [Related]
22. Analysis of genetic alterations related to the development and progression of breast carcinoma.
Nagayama K; Watatani M
Jpn J Cancer Res; 1993 Nov; 84(11):1159-64. PubMed ID: 7903963
[TBL] [Abstract][Full Text] [Related]
23. Prognostic factors for recurrent breast cancer: univariate and multivariate analyses including histologic grade and amplification of the c-erbB-2 proto-oncogene.
Tsuda H; Tsugane S; Fukutomi T; Nanasawa T; Yamamoto H; Hirohashi S
Jpn J Clin Oncol; 1992 Aug; 22(4):244-9. PubMed ID: 1359174
[TBL] [Abstract][Full Text] [Related]
24. Genetic studies of 457 breast cancers. Clinicopathologic parameters compared with genetic alterations.
Harada Y; Katagiri T; Ito I; Akiyama F; Sakamoto G; Kasumi F; Nakamura Y; Emi M
Cancer; 1994 Oct; 74(8):2281-6. PubMed ID: 7922980
[TBL] [Abstract][Full Text] [Related]
25. Chromosome 11q13, c-erbB-2, and c-myc amplification in invasive breast carcinoma: clinicopathologic correlations.
Gaffey MJ; Frierson HF; Williams ME
Mod Pathol; 1993 Nov; 6(6):654-9. PubMed ID: 7905628
[TBL] [Abstract][Full Text] [Related]
26. Oncogene protein co-expression. Value of Ha-ras, c-myc, c-fos, and p53 as prognostic discriminants for breast carcinoma.
Bland KI; Konstadoulakis MM; Vezeridis MP; Wanebo HJ
Ann Surg; 1995 Jun; 221(6):706-18; discussion 718-20. PubMed ID: 7794075
[TBL] [Abstract][Full Text] [Related]
27. A prospective study of the significance of gene and chromosome alterations as prognostic indicators of breast cancer patients with lymph node metastases.
Tsuda H; Sakamaki C; Tsugane S; Fukutomi T; Hirohashi S
Breast Cancer Res Treat; 1998 Mar; 48(1):21-32. PubMed ID: 9541186
[TBL] [Abstract][Full Text] [Related]
28. DNA amplifications and elevated expression of proto-oncogene in addition to altered DNA ploidy in metastatic brain tumors.
Arai T; Ichimura K; Hirakawa K; Yuasa Y
Clin Exp Metastasis; 1994 Jul; 12(4):267-75. PubMed ID: 7913669
[TBL] [Abstract][Full Text] [Related]
29. [Correlation between DNA content and amplification of oncogenes (c-myc, L-myc, c-erbB-2) and correlation with prognosis in 143 cases of resected lung cancer].
Chiba W; Sawai S; Hanawa T; Ishida H; Matsui T; Kosaba S; Watanabe S; Hatakenaka R; Matsubara Y; Funatsu T
Gan To Kagaku Ryoho; 1993 Apr; 20(6):824-7. PubMed ID: 8098200
[TBL] [Abstract][Full Text] [Related]
30. int-2 and c-erbB-2 gene amplification detected in 70 frozen human breast carcinomas by quantitative polymerase chain reaction.
An HX; Niederacher D; Dominik SI; Kuschel B; Yan H; Dall P; Schnürch HG; Bender HG; Beckmann MW
Anticancer Res; 1997; 17(4B):3133-6. PubMed ID: 9329619
[TBL] [Abstract][Full Text] [Related]
31. ERBB2 amplification in breast cancer with a high rate of proliferation.
Borg A; Baldetorp B; Fernö M; Killander D; Olsson H; Sigurdsson H
Oncogene; 1991 Jan; 6(1):137-43. PubMed ID: 1671531
[TBL] [Abstract][Full Text] [Related]
32. Analysis of oncogenes and tumor suppressor genes in human breast cancer.
Yamashita H; Kobayashi S; Iwase H; Itoh Y; Kuzushima T; Iwata H; Itoh K; Naito A; Yamashita T; Masaoka A
Jpn J Cancer Res; 1993 Aug; 84(8):871-8. PubMed ID: 8104920
[TBL] [Abstract][Full Text] [Related]
33. Overexpression of either c-myc or c-erbB-2/neu proto-oncogenes in human breast carcinomas: correlation with poor prognosis.
Guérin M; Barrois M; Terrier MJ; Spielmann M; Riou G
Oncogene Res; 1988; 3(1):21-31. PubMed ID: 2905033
[TBL] [Abstract][Full Text] [Related]
34. Genetic alterations of c-myc, c-erbB-2, and c-Ha-ras protooncogenes and clinical associations in human breast carcinomas.
Garcia I; Dietrich PY; Aapro M; Vauthier G; Vadas L; Engel E
Cancer Res; 1989 Dec; 49(23):6675-9. PubMed ID: 2573420
[TBL] [Abstract][Full Text] [Related]
35. Cyclin DI amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis.
Seshadri R; Lee CS; Hui R; McCaul K; Horsfall DJ; Sutherland RL
Clin Cancer Res; 1996 Jul; 2(7):1177-84. PubMed ID: 9816285
[TBL] [Abstract][Full Text] [Related]
36. Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry.
Salido M; Tusquets I; Corominas JM; Suarez M; Espinet B; Corzo C; Bellet M; Fabregat X; Serrano S; Solé F
Breast Cancer Res; 2005; 7(2):R267-73. PubMed ID: 15743507
[TBL] [Abstract][Full Text] [Related]
37. Allelic loss on distal chromosome 17p is associated with poor prognosis in a group of Brazilian breast cancer patients.
Nagai MA; Pacheco MM; Brentani MM; Marques LA; Brentani RR; Ponder BA; Mulligan LM
Br J Cancer; 1994 Apr; 69(4):754-8. PubMed ID: 7908218
[TBL] [Abstract][Full Text] [Related]
38. Activated oncogenes and putative tumor suppressor genes involved in human breast cancers.
Tripathy D; Benz CC
Cancer Treat Res; 1992; 63():15-60. PubMed ID: 1363356
[TBL] [Abstract][Full Text] [Related]
39. [DNA analysis of breast cancer].
Ohuchi N; Mori S
Gan To Kagaku Ryoho; 1991 Jan; 18(1):30-6. PubMed ID: 1987899
[TBL] [Abstract][Full Text] [Related]
40. Amplification of c-myc and c-erbB-2 proto-oncogenes in human solid tumors: frequency and clinical significance.
Gutman M; Ravia Y; Assaf D; Yamamoto T; Rozin R; Shiloh Y
Int J Cancer; 1989 Nov; 44(5):802-5. PubMed ID: 2573579
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
